Biotime News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

13.09.18	BioTime schliesst Verkauf von AgeX-Anteilen an Juvenescence in Höhe von 43,2 Millionen USD ab (Businesswire)
28.08.18	BioTime’s CEO Adi Mohanty and CFO Russell Skibsted to Participate in Upcoming Panel and Conferences (Businesswire)
16.08.18	BioTime to Present Data at the Military Health System Research Symposium (Businesswire)
02.08.18	BioTime Reports Second Quarter Results and Recent Corporate Accomplishments (Businesswire)
02.08.18	BioTime to Receive $43 Million From Juvenescence (Businesswire)
02.08.18	BioTime Announces the Start of an Investigator Initiated Study of Premvia™ Designed and Conducted by Dr. Gordon H. Sasaki (Businesswire)
02.08.18	BioTime Announces Distribution Ratio for Distribution of AgeX Therapeutics Shares (Businesswire)
25.07.18	Data from BioTime’s OpRegen® Program to Be Presented at AAO 2018 (Businesswire)
23.07.18	BioTime to Announce Second Quarter 2018 Results on August 2, 2018 (Businesswire)
11.07.18	AgeX Therapeutics CEO Dr. Michael D. West to Present at Ending Age-Related Diseases: Investment Prospects & Advances in Research, July 12 in New York City (Businesswire)
10.07.18	BioTime Announces July 31, 2018 Record Date for the Distribution of AgeX Therapeutics Shares (Businesswire)
29.06.18	BioTime Awarded Grant From the NIH (Businesswire)
25.06.18	BioTime Licenses GMP Cell Line to Goliver Therapeutics (Businesswire)
11.06.18	AgeX Therapeutics Closes on $5 Million Strategic Investment From Juvenescence (Businesswire)
08.06.18	BioTime Announces Submission of Draft Registration Statement for a Proposed Distribution of Its AgeX Shares (Businesswire)
05.06.18	AgeX Therapeutics Appoints John F. Mauldin to Board of Directors (Businesswire)
30.05.18	BioTime to Present at the 8th Annual LD Micro Invitational (Businesswire)
29.05.18	BioTime Announces $1.9 Million Grant for Continued Development of OpRegen® for Dry-AMD (Businesswire)
29.05.18	BioTime erhält Zuschuss in Höhe von 1,9 Millionen US-Dollar für Weiterentwicklung von OpRegen® für Dry-AMD (Businesswire)
24.05.18	BioTime Further Expands OpRegen® Clinical Trial in Dry-AMD With the Opening of Two Additional U.S. Sites (Businesswire)
17.05.18	AgeX Therapeutics CEO Dr. Michael D. West to Deliver Keynote Address at World Advanced Therapies & Regenerative Medicine Congress, May 18 in London (Businesswire)
10.05.18	BioTime Reports First Quarter Results and Recent Corporate Accomplishments (Businesswire)
02.05.18	AgeX Announces NIH Grant Award (Businesswire)
01.05.18	BioTime Presents Updated OpRegen® Clinical Trial Data at ARVO (Businesswire)
26.04.18	BioTime to Announce First Quarter 2018 Results on May 10, 2018 (Businesswire)
16.04.18	Data from BioTime’s OpRegen® and Retinal Restoration Programs to Be Presented at ARVO 2018 (Businesswire)
09.04.18	Data from BioTime’s OpRegen® Program to Be Presented at the Fifth Annual Retinal Cell and Gene Therapy Innovation Summit (Businesswire)
27.03.18	BioTime Announces Cash Sale of Ascendance Biotechnology (Businesswire)
13.03.18	BioTime Submits CE Mark Application for European Approval of Renevia® (Businesswire)
07.03.18	BioTime Announces DSMB Approval to Proceed to Cohort 4 of the OpRegen® Clinical Trial (Businesswire)
05.03.18	BioTime to Announce Fourth Quarter and Fiscal 2017 Results on March 15, 2018 (Businesswire)
01.03.18	AgeX Therapeutics CEO Dr. Michael D. West to Present at Three Conferences in March 2018 (Businesswire)
28.02.18	BioTime to Present at the Raymond James 39th Annual Institutional Investor Conference (Businesswire)
26.02.18	BioTime Announces Appointment of Gary S. Hogge, DVM, MS, PhD, as Sr. Vice President, Clinical and Medical Affairs (Businesswire)
22.02.18	BioTime Appoints Cavan Redmond to Its Board of Directors (Businesswire)
15.02.18	Data from BioTime's OpRegen® and Vision Restoration Programs to Be Presented at ARVO 2018 (Businesswire)
07.02.18	BioTime to Participate at the BIO CEO and Investor Conference in New York, February 12th and 13th 2018 (Businesswire)
29.01.18	Renevia® Data From the Successful Pivotal Trial to Be Presented at the IMCAS Conference (Businesswire)
23.01.18	BioTime to Present at the Noble Capital Markets 14th Annual Institutional Investor Conference in Fort Lauderdale, January 29, 2018 (Businesswire)
22.01.18	BioTime Announces Clinical and Corporate Milestone Targets for 2018 (Businesswire)
18.01.18	AgeX CEO Michael D. West to Present in Plenary Session at The World Stem Cell Summit on "Stem Cell Innovations That Will Change the World” (Businesswire)
17.01.18	BioTime Announces Issuance of 41 New Patents to Expand and Bolster Its Patent Estate (Businesswire)
05.01.18	AgeX Therapeutics to Present at Biotech Showcase Annual Conference (Businesswire)
02.01.18	AgeX Therapeutics Identifies Genes Implicated in Tissue Regeneration and Cancer (Businesswire)
20.12.17	BioTime to Participate in The LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018 (Businesswire)
04.12.17	Additional Renevia Data From the Successful Pivotal Trial Was Presented at the IFATS Conference (Businesswire)
30.11.17	Data from BioTime’s Renevia® Program to Be Presented at IFATS Conference (Businesswire)
15.11.17	BioTime Presents Updated OpRegen® Phase I/IIa Trial Data at AAO (Businesswire)
13.11.17	BioTime to Participate in Upcoming Conferences (Businesswire)
09.11.17	BioTime Reports Third Quarter Results and Recent Corporate Accomplishments (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Logitech Intl	81.38	1.85 %	K V
Kuehne+Nagel Int	207.00	1.17 %	K V
Lonza Grp	582.60	0.38 %	K V
Swiss Life Hldg	734.20	0.33 %	K V
CieFinRichemont	168.70	0.27 %	K V
Roche Hldg G	273.20	-0.22 %	K V
Alcon	80.70	-0.25 %	K V
Nestle	73.92	-0.35 %	K V
ABB	53.24	-0.60 %	K V
Sonova Hldg	313.90	-1.44 %	K V

Nachrichten zu Biotime IncShs

Aktien Top/Flop

Meistgelesene Nachrichten